This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Study Evaluating Eculizumab (Soliris®) In Preventing Antibody-Mediated Rejection (AMR) In Kidney Transplant Recipients Presented At The European Society For Organ Transplantation (ESOT) Annual Congress

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers have presented preliminary data from a single-arm Phase 2 study of eculizumab (Soliris ®) as an investigational therapy to prevent acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients. The composite primary endpoint was the nine-week occurrence of post-transplantation treatment failure, which occurred in 10.6% of the 47 patients reported today, including a 6.4% rate of AMR 1 compared to an expected 30% rate of AMR 2 in this highly sensitized population of kidney transplant recipients. The data were presented today in an oral presentation at the 2013 annual congress of the European Society for Organ Transplantation (ESOT) in Vienna, Austria.

Acute AMR can lead to severe kidney allograft damage resulting in rapid loss of function and possible loss of the transplanted kidney, which makes AMR a significant clinical barrier to transplantation in sensitized patients. 3 Research suggests that uncontrolled activation of complement, triggered by the binding of donor-specific antibodies (DSAs) to their target proteins (antigens) of the donor kidney, may be the primary reason for acute AMR in kidney transplant recipients who are sensitized, or have DSAs, to their donors. 3,4 Prophylaxis with a terminal complement inhibitor, such as eculizumab, is thus considered a potential strategy to prevent acute AMR. There are no approved treatments for the prevention of acute AMR.

“Approximately 30% of kidney transplant candidates on waiting lists are sensitized, or have antibodies, to potential donors. Because conventional immunosuppressive therapies are ineffective for the prevention of AMR, sensitized patients often have to wait years for a kidney suitable for transplantation. Thus, AMR has emerged as a significant, long-standing clinical problem in transplantation,” said Denis Glotz, M.D., Ph.D., Chief of the Department of Nephrology and Transplantation at Saint-Louis Hospital in Paris, France. “The data from this study suggest that eculizumab may be an effective prophylaxis against acute AMR in kidney recipients with preexisting antibodies against their donor.”

1 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.12 -200.19 -1.11%
S&P 500 2,067.89 -18.35 -0.88%
NASDAQ 4,900.8850 -46.5560 -0.94%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs